Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T27999
|
||||
| Former ID |
TTDR00859
|
||||
| Target Name |
Protective antigen
|
||||
| Gene Name |
pagA
|
||||
| Synonyms |
Anthrax toxins translocating protein; Bacillus anthracis protective antigen; PA; PA-83; PA83; pagA
|
||||
| Target Type |
Successful
|
||||
| Disease | Anthrax [ICD9: 22; ICD10: A00-B99] | ||||
| Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | |||||
| Bacillus anthracis infection [ICD10: A22] | |||||
| Function |
One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death wheninjected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.
|
||||
| BioChemical Class |
Bacillus anthracis protective antigen
|
||||
| UniProt ID | |||||
| Sequence |
MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQA
PMVVTSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWV DDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNL QLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIH EKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIIL SKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSST VAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTL ATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLD TDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPS DPLETTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNA TNIYTVLDKIKLNAKMNILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNI DKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISN PNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Raxibacumab | Drug Info | Approved | Anthrax | [1] |
| AVP-21D9 | Drug Info | Phase 1 | Bacillus anthracis infection | [2] | |
| IQ-DAA | Drug Info | Phase 1 | Bacillus anthracis infection | [3] | |
| Valortim | Drug Info | Phase 1 | Bacterial infections | [4] | |
| Anthrax vaccine | Drug Info | Discontinued in Phase 1 | Bacillus anthracis infection | [5] | |
| Modulator | IQ-DAA | Drug Info | |||
| Raxibacumab | Drug Info | [1] | |||
| Pathways | |||||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | ||||
| Reactome | Uptake and function of anthrax toxins | ||||
| References | |||||
| REF 1 | Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. | ||||
| REF 2 | ClinicalTrials.gov (NCT01202695) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9). U.S. National Institutes of Health. | ||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020942) | ||||
| REF 4 | ClinicalTrials.gov (NCT01265745) Dose Escalation Study of Valortim (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects. U.S. National Institutes of Health. | ||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017549) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.